Marshall Wace, LLP Alector, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Alector, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 54,000 shares of ALEC stock, worth $219,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,000

Previous 52,609 2.64%

Holding current value

$219,780

Previous $238,000 5.88%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.34 - $6.58 $6,036 - $9,152	1,391 Added 2.64%	54,000 $252,000
Q2 2024 Aug 14, 2024	SELL	$4.19 - $6.23 $522,363 - $776,687	-124,669 Reduced 70.32%	52,609 $238,000
Q1 2024 May 15, 2024	BUY	$5.69 - $8.08 $1.01 Million - $1.43 Million	177,278 New	177,278 $1.07 Million
Q2 2022 Aug 15, 2022	BUY	$7.65 - $14.24 $908,146 - $1.69 Million	118,712 Added 23.22%	629,852 $6.4 Million
Q1 2022 May 16, 2022	SELL	$13.02 - $20.78 $7.42 Million - $11.8 Million	-569,714 Reduced 52.71%	511,140 $7.28 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $25.54 $14.9 Million - $19.6 Million	768,293 Added 245.81%	1,080,854 $22.3 Million
Q3 2021 Nov 15, 2021	BUY	$21.65 - $39.49 $6.77 Million - $12.3 Million	312,561 New	312,561 $7.13 Million
Q1 2021 May 17, 2021	SELL	$14.84 - $22.23 $1.19 Million - $1.79 Million	-80,371 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.4 - $16.7 $479,841 - $852,484	-51,047 Reduced 38.84%	80,371 $1.22 Million
Q3 2020 Nov 16, 2020	BUY	$10.54 - $24.96 $402,427 - $952,997	38,181 Added 40.95%	131,418 $1.39 Million
Q2 2020 Aug 13, 2020	BUY	$21.87 - $33.11 $2.04 Million - $3.09 Million	93,237 New	93,237 $2.28 Million
Q1 2020 May 15, 2020	SELL	$16.25 - $35.28 $259,480 - $563,351	-15,968 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$14.17 - $20.3 $226,266 - $324,150	15,968 New	15,968 $275,000

Others Institutions Holding ALEC

# of Institutions

167

Shares Held

57.8M

Call Options Held

146K

Put Options Held

90.8K

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $336M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Alector, Inc. Transaction History